Cure8 research brief
Intestinal fibrosis causes strictures that often need surgery and has few effective medical treatments; linking the microbiome to fibrogenesis suggests new prevention or treatment strategies that could reduce surgery risk.
Adults with Crohn's disease (especially those with or at risk for fibrostenotic disease), clinicians managing Crohn's disease, and researchers studying the microbiome, immune pathways, or anti-fibrotic therapies.
This is a review article summarizing evidence that microbial dysbiosis — including expansion of pathobionts such as adherent-invasive E. coli and Clostridium innocuum — may promote fibrogenesis in the intestine through direct fibroblast activation (via pattern recognition receptors) and indirect immune pathways (macrophage polarization, Th17 responses).
The authors also describe the concept that bacterial translocation into mesenteric fat and the “creeping fat” axis can create a profibrotic environment.
The review discusses therapeutic implications without reporting new clinical trial results: it proposes precision microbiome modulation or metabolite-based interventions as promising research directions, but these remain investigational.
This is a narrative review (Intestinal Research) summarizing mechanistic and translational evidence; it does not present new clinical trial results. Microbiome-targeted anti-fibrotic approaches are proposed but remain investigational.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
